Related Experiment Video
Updated: Aug 9, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
[Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia]
Hirokazu Kanegane1, Keiko Nomura, Takeshi Futatani
1Department of Pediatrics, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630, Toyama Sugitani 930-0194, Japan.
Abstract:
Intravenous immunoglobulin (IVIG) replacement therapy is the mainstay of therapy for X linked agammaglobulinemia (XLA). This study was attempted to investigate how patients with XLA were treated with IVIG in Japan. Data were complied from questionnaires filled in by the physicians. One hundred eighteen medical records had been given from 134 patients. One hundred eleven patients had been treated with IVIG. Most patients had been administered IVIG every 2 to 4 weeks, and maintained serum IgG trough levels of 400 mg/dl. Some of patients had adverse effects of IVIG. Antibiotics, especially macrolides, had been administered in some of patients. A few patients, despite the maintenance of higher trough levels, were associated with infections. The present study suggests that IVIG should be administered dependent on personal infection histories.
Related Concept Videos
Tumor Immunotherapy
Gene Therapy
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Continuous Renal Replacement Therapy

